The most common CRISPR Therapeutics email format is [first]. [last] (ex. [email protected]), which is being used by 52.4% of CRISPR Therapeutics work email addresses.

Mandy Tam, based in Cambridge, Massachusetts, United States, is currently a CRISPR Therapeutics at CRISPR Therapeutics. Mandy Tam brings experience from previous roles at …

From streamlined approaches to licensing through full technical and regulatory support from our industry-leading experts, Synthego is enabling greater access to CRISPR technology driving …

Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology …

We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system …

The company is the first to apply CRISPR technology for the purposes of species de-extinction. Colossal is accepting humanity’s duty to restore Earth to a healthier state, while also solving …

Jenthera Therapeutics is a preclinical gene editing company developing a novel direct protein delivery CRISPR platform towards the development of groundbreaking therapeutics in oncology.

Founded by a seasoned team of experts in drug R&D service, Enqu Bio offers comprehensive services that include 1- Discovery Biology (target validation, cell line generation, CRISPR …

Jon Terrett, based in Cambridge, MA, US, is currently a Head Of Research at CRISPR Therapeutics. Jon Terrett brings experience from previous roles at CytomX Therapeutics, …

Our solution employs forefront synthetic biology techniques to genetically engineer anaerobic, spore-forming bacteria (Clostridium Sporogenes) with CRISPR-Cas9 gene editing and allelic …